Pharmaunternehmen meldet bahnbrechende Arzneimittelformulierung
www.finanznachrichten.de/...-arzneimittelformulierung-670.htm
Core One Labs Inc.
core1labs.com/
|
124 Beiträge ausgeblendet. |
|
Core One signs deal for potential sale of psilocybin
2023-12-08 19:02 ET - News Release
Mr. Joel Shacker reports
CORE ONE LABS INC. ANNOUNCES INITIAL AGREEMENT FOR POTENTIAL SALE OF PROPRIETARY BIOSYNTHETIC PSILOCYBIN, FACILITATING ENTRY INTO THE INTERNATIONAL MARKET
Core One Labs Inc. has signed an initial agreement with Cube Psytech Corp., marking a significant step toward exploring the potential sale of biosynthetically produced psilocybin, or the licensing of its proprietary method for biosynthetic psilocybin production technology. This agreement with Cube Psytech could set the stage for Core One products to enter the international market:
https://www.stockwatch.com/News/Item/Z-C!COOL-3491211/C/COOL ...
... auf den Weg. - Aktuelle Quelle hierzu, und zwar vom 15. Januar 2024:
www.nasdaq.com/articles/...ssion-with-psilocybin-research-for ...
Charbonneau, head of the study committee, has already initiated discussions with Indiana University Health and Purdue University about psychedelics research.
“I have had discussions with both IU Health and with Purdue University,” said Charbonneau. “I spoke to 150 pharmacy students at Purdue, and afterward had a chance to speak with the dean of the pharmacy program … and he texted Dr. Jerome Adams, who’s now at Purdue University.”
Adams, the U.S. Surgeon General under Donald Trump, is apparently open to exploring psilocybin despite his past skepticism towards medical marijuana.
“A growing body of research suggests that, when administered in controlled conditions with supportive therapy, (psilocybin) may be useful for treating various psychiatric disorders, like depression,” the American Society for Microbiology noted in a post last year, which the Courier And Press mentioned. “However, there are questions surrounding psilocybin’s mechanism of action, as well as stigma, funding and regulatory hurdles, that must be addressed before psilocybin could be adopted for regular therapeutic use.”
Soweit der hier zitierte Ausschnitt. - Den vollständigen Artikel findet Ihr unter dem oben angegebenen Link.
... des Patent-Halters Core One Labs Inc. auswirken wird, bleibt abzuwarten ...
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
149 | Core One Labs Inc. - Pharmaunternehmen | brunneta | Yortor | 14.10.24 16:50 | ||
2 | 315 | Core One L. beantragt NASDAQ Listing. 100% heute? | Global-Invest | Claudimal | 02.05.23 08:19 | |
15 | Core One Labs auf dem Weg zur Nasdaq! | Share Agent | janstein | 21.06.21 07:49 | ||
4 | 230 | Neuer Name... | hewi62 | HonestMeyer | 06.05.21 09:34 | |
1 | biosynthetisches Psilocybin mittels Bakteriums | bozkurt7 | bozkurt7 | 24.04.21 23:36 |